BR112022021065A2 - Anticorpos terapêuticos de musk - Google Patents
Anticorpos terapêuticos de muskInfo
- Publication number
- BR112022021065A2 BR112022021065A2 BR112022021065A BR112022021065A BR112022021065A2 BR 112022021065 A2 BR112022021065 A2 BR 112022021065A2 BR 112022021065 A BR112022021065 A BR 112022021065A BR 112022021065 A BR112022021065 A BR 112022021065A BR 112022021065 A2 BR112022021065 A2 BR 112022021065A2
- Authority
- BR
- Brazil
- Prior art keywords
- musk
- antibodies
- therapeutic
- present
- musk antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011986P | 2020-04-17 | 2020-04-17 | |
| US202063038633P | 2020-06-12 | 2020-06-12 | |
| US202063112375P | 2020-11-11 | 2020-11-11 | |
| PCT/US2021/027801 WO2021212053A2 (en) | 2020-04-17 | 2021-04-16 | Therapeutic musk antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021065A2 true BR112022021065A2 (pt) | 2023-02-23 |
Family
ID=75850676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021065A BR112022021065A2 (pt) | 2020-04-17 | 2021-04-16 | Anticorpos terapêuticos de musk |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11492401B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4136115A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7772715B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230028217A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115843268A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021256049A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021065A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175597A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297295A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011856A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022552483A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021212053A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022552483A1 (en) * | 2020-04-17 | 2024-02-05 | argenx BV | Therapeutic musk antibodies |
| US20240279331A1 (en) * | 2021-06-11 | 2024-08-22 | The Regents Of The University Of California | Antibodies that stimulate nk cell-mediated cytotoxicity |
| MX2024008933A (es) * | 2022-01-28 | 2024-09-30 | argenx BV | Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares. |
| WO2023218099A1 (en) * | 2022-05-13 | 2023-11-16 | argenx BV | In utero treatment of a fetus having genetic disease/neuromuscular disease |
| WO2024235870A1 (en) * | 2023-05-15 | 2024-11-21 | Argenx B.V. | Antibodies for use in agrin-deficient disorders |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
| WO2026152042A1 (en) | 2025-01-10 | 2026-07-16 | Scholar Rock, Inc. | A novel class of musk agonists and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5814478A (en) | 1995-12-15 | 1998-09-29 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
| US6737249B1 (en) | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
| US6624819B1 (en) | 2000-05-01 | 2003-09-23 | Broadcom Corporation | Method and system for providing a flexible and efficient processor for use in a graphics processing system |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| EP1411851B1 (en) | 2001-08-03 | 2006-11-02 | Tyco Healthcare Group LP | Marker for use with a tissue marking apparatus |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| JP2011207769A (ja) | 2010-03-29 | 2011-10-20 | Arubion:Kk | 化粧料及び皮膚外用剤 |
| WO2013074636A1 (en) | 2011-11-14 | 2013-05-23 | New York University | Muscle specific receptor kinase and modulation thereof |
| WO2015039015A2 (en) | 2013-09-13 | 2015-03-19 | New York University | Methods for treating muscle specific receptor kinase myasthenia gravis |
| PH12022552483A1 (en) * | 2020-04-17 | 2024-02-05 | argenx BV | Therapeutic musk antibodies |
-
2021
- 2021-04-16 PH PH1/2022/552483A patent/PH12022552483A1/en unknown
- 2021-04-16 BR BR112022021065A patent/BR112022021065A2/pt unknown
- 2021-04-16 CA CA3175597A patent/CA3175597A1/en active Pending
- 2021-04-16 EP EP21724109.0A patent/EP4136115A2/en active Pending
- 2021-04-16 WO PCT/US2021/027801 patent/WO2021212053A2/en not_active Ceased
- 2021-04-16 IL IL297295A patent/IL297295A/en unknown
- 2021-04-16 AU AU2021256049A patent/AU2021256049A1/en active Pending
- 2021-04-16 CN CN202180035285.0A patent/CN115843268A/zh active Pending
- 2021-04-16 MX MX2022011856A patent/MX2022011856A/es unknown
- 2021-04-16 KR KR1020227035693A patent/KR20230028217A/ko active Pending
- 2021-04-16 JP JP2022563016A patent/JP7772715B2/ja active Active
- 2021-12-30 US US17/565,994 patent/US11492401B2/en active Active
-
2022
- 2022-10-03 US US17/937,630 patent/US20230151091A1/en active Pending
-
2025
- 2025-11-06 JP JP2025187491A patent/JP2026056615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175597A1 (en) | 2021-10-21 |
| US20220259304A1 (en) | 2022-08-18 |
| IL297295A (en) | 2022-12-01 |
| JP2026056615A (ja) | 2026-04-01 |
| JP2023522212A (ja) | 2023-05-29 |
| US20230151091A1 (en) | 2023-05-18 |
| WO2021212053A8 (en) | 2022-09-29 |
| PH12022552483A1 (en) | 2024-02-05 |
| KR20230028217A (ko) | 2023-02-28 |
| EP4136115A2 (en) | 2023-02-22 |
| CN115843268A (zh) | 2023-03-24 |
| WO2021212053A2 (en) | 2021-10-21 |
| MX2022011856A (es) | 2023-02-23 |
| AU2021256049A1 (en) | 2022-11-03 |
| US11492401B2 (en) | 2022-11-08 |
| JP7772715B2 (ja) | 2025-11-18 |
| WO2021212053A3 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552483A1 (en) | Therapeutic musk antibodies | |
| BRPI0821658B8 (pt) | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos | |
| BR112021014074A2 (pt) | Proteínas de ligação ao antígeno anti-receptor il2 gama | |
| BR112019005670A2 (pt) | anticorpos anti-muc16 (mucina 16) | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| BR112022016232A2 (pt) | Proteínas biespecíficas anti-her2 manipuladas | |
| BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| JOP20180117B1 (ar) | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها | |
| BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| BR112022011037A2 (pt) | Anticorpos ddr1 novos e usos dos mesmos | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| BR112022022986A2 (pt) | Anticorpos anti-hemojuvelina (hjv) para tratar mielofibrose | |
| MY206214A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| MX2023014069A (es) | Composiciones y métodos para el tratamiento del cáncer de próstata. | |
| BR112023002301A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| BR112022026922A2 (pt) | Anticorpo anti-lilrb1 e usos do mesmo | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: NEW YORK UNIVERSITY (US) ; ARGENX IIP BV (BE) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO 870230041244 DE 17/05/2023, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DO DEPOSITANTE CONSTANTE NOS DOCUMENTOS APRESENTADOS ?ARGENX BENELUX? E O CONSTANTE NO FORMULARIO ?ARGENX BENELUX BV?. |
|
| B25D | Requested change of name of applicant approved |
Owner name: NEW YORK UNIVERSITY (US) ; ARGENX BENELUX BV (BE) |
|
| B25A | Requested transfer of rights approved |
Owner name: NEW YORK UNIVERSITY (US) ; ARGENX BV (BE) |